Subscribe
shutterstock_1349461187_pavel_kapysh
Pavel Kapysh / Shutterstock.com
25 November 2021Big Pharma

Court denies Sun Pharma’s bid to avoid trial

Sun Pharma’s bid to avoid facing a trial over allegations of antitrust behaviour by an Indian drugmaker it acquired has been denied by a Massachusetts court.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Intubated patients sedative patent the focus of ACS Dobfar suit
16 December 2021   Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.
Big Pharma
Fed Circ denies Sun Pharma patent for alopecia treatment
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Americas
Intubated patients sedative patent the focus of ACS Dobfar suit
16 December 2021   Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.
Big Pharma
Fed Circ denies Sun Pharma patent for alopecia treatment
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.

More on this story

Americas
Intubated patients sedative patent the focus of ACS Dobfar suit
16 December 2021   Sun Pharmaceutical has been sued by ACS Dobfar subsidiary InfoRLife and WG Critical Care for allegedly infringing on a patent with its proposed midazolam-an anaesthesia medication.
Big Pharma
Sun unit resolves antitrust lawsuit for $485m
24 March 2022   Sun Pharmaceuticals has agreed to pay $485 million to settle an antitrust lawsuit relating to a generic drug application filed by its subsidiary, Ranbaxy, ending years of litigation.
Big Pharma
Fed Circ denies Sun Pharma patent for alopecia treatment
24 August 2023   Indian drugmaker had challenged PTAB decision that patent for new version of ruxolitinib was invalid as obvious | Decision hands a victory to US rival.

More features

President Trump 2.0: Five major areas to watch
Startup CFO’s betrayal is a lesson in preparing for the worst
Sandoz lands reduced antitrust award of $70m
New president’s to-do list: Patent bills, non-competes, USPTO director?
Sanofi subsidiary fends off $450m trade secrets case
Regulatory expert joins White & Case
Teva faces $500m fine for antitrust breaches over MS drug
UK Budget: A missed opportunity?